Urotensin II induces transactivation of the epidermal growth factor receptor via transient oxidation of SHP-2 in the rat renal tubular cell line NRK-52E

Growth Factors

Volumn 27, Issue 3, 2009, Pages 155-162

  Sue, Yuh Mou ^a,b   Chen, Cheng Hsien ^a,b   Hsu, Yung Ho ^a,b   Hou, Chun Cheng ^a,b   Cheng, Chung Yi ^a   Chen, Yen Cheng ^a   Lin, Shih Li ^a   Chen, Tzen Wen ^b,c   Chen, Tso Hsiao ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Epidermal growth factor receptor transactivation; Rat renal proximal tubular cells; Reactive oxygen species; Src homology 2 containing phosphotyrosine phosphatase; Urotensin II

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; REACTIVE OXYGEN METABOLITE; UROTENSIN II; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ACETYLCYSTEINE; FLAVONOID; UROTENSIN;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN NRK 52E; CONCENTRATION RESPONSE; CONTROLLED STUDY; IMMUNOPRECIPITATION; KIDNEY TUBULE CELL; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RAT; RAT STRAIN; SIGNAL TRANSDUCTION; TRANSACTIVATION; ANIMAL; CELL LINE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; KIDNEY PROXIMAL TUBULE; METABOLISM; OXIDATION REDUCTION REACTION; PHOSPHORYLATION; PHYSIOLOGY; TRANSCRIPTION INITIATION;

RATTUS;

ACETYLCYSTEINE; ANIMALS; CELL LINE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; HUMANS; KIDNEY TUBULES, PROXIMAL; OXIDATION-REDUCTION; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; RATS; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTIONAL ACTIVATION; UROTENSINS;

EID: 67651214385     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.1080/08977190902879866     Document Type: Article

References (31)

1. Ashton N. 2006. Renal and vascular actions of urotensin II. Kidney Int 70:624-629.
2. Chen CH, Cheng TH, Lin H, Shih NL, Chen YL, Chen YS, Cheng CF, Lian WS, Meng TC, Chiu WT, Chen JJ. 2006. Reactive oxygen species generation is involved in epidermal growth factor receptor transactivation through the transient oxidization of Src homology 2-containing tyrosine phosphatase in endothelin-1 signaling pathway in rat cardiac fibroblasts. Mol Pharmacol 69: 1347-1355.
3. Chen YL, Liu JC, Loh SH, Chen CH, Hong CY, Chen JJ, Cheng TH. 2008. Involvement of reactive oxygen species in urotensin II-induced proliferation of cardiac fibroblasts. Eur J Pharmacol 593:24-29.
4. Chiarugi P, Cirri P. 2003. Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. Trends Biochem Sci 28:509-514.
5. Cook R, Wu CC, Kang YJ, Han J. 2007. The role of the p38 pathway in adaptive immunity. Cell Mol Immunol 4:253-259.
6. Djordjevic T, BelAiba RS, Bonello S, Pfeilschifter J, Hess J, Gorlach A. 2005. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 25:519-525.
7. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN. 2000. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131:1262-1274.
8. Douglas SA, Dhanak D, Johns DG. 2004. From "gills to pills": Urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 25:76-85
9. Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T. 2001. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 276:7957-7962.
10. Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A. 2001. Cell communication networks: Epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 20:1594-1600.
11. Kanda Y, Mizuno K, Kuroki Y, Watanabe Y. 2001. Thrombin-induced p38 mitogen-activated protein kinase activation is mediated by epidermal growth factor receptor transactivation pathway. Br J Pharmacol 132:1657-1664.
12. Leserer M, Gschwind A, Ullrich A. 2000. Epidermal growth factor receptor signal transactivation. IUBMB Life 49:405-409.
13. Liu KD, Brakeman PR. 2008. Renal repair and recovery. Crit Care Med 36:S187-S192.
14. Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, Hirata Y. 2001. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 19:2185-2190.
15. Matsushita M, Shichiri M, Fukai N, Ozawa N, Yoshimoto T, Takasu N, Hirata Y. 2003. Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. Endocrinology 144:1825-1831.
16. Meng TC, Fukada T, Tonks NK. 2002. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 9: 387-399.
17. Meng TC, Buckley DA, Galic S, Tiganis T, Tonks NK. 2004. Regulation of insulin signaling through reversible oxidation of the protein-tyrosine phosphatases TC45 and PTP1B. J Biol Chem 279:37716-37725.
18. Onan D, Pipolo L, Yang E, Hannan RD, Thomas WG. 2004. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol 18: 2344-2354.
19. Ong KL, Lam KS, Cheung BM. 2005. Urotensin II: Its function in health and its role in disease. Cardiovasc Drugs Ther 19:65-75.
20. Ravani P, Tripepi G, Pecchini P, Mallamaci F, Malberti F, Zoccali C. 2008. Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney disease. Kidney Int 73: 95-101.
21. Salmeen A, Andersen JN, Myers MP, Meng TC, Hinks JA, Tonks NK, Barford D. 2003. Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nature 423:769-773.
22. Salmeen A, Barford D. 2005. Functions and mechanisms of redox regulation of cysteine-based phosphatases. Antioxid Redox Signal 7:560-577.
23. Sauzeau V, Le Mellionnec E, Bertoglio J, Scalbert E, Pacaud P, Loirand G. 2001. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 88:1102-1104.
24. Saxton TM, Henkemeyer M, Gasca S, Shen R, Rossi DJ, Shalaby F, Feng GS, Pawson T. 1997. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. Embo J 16:2352-2364.
25. Shah BH, Catt KJ. 2003. A central role of EGF receptor transactivation in angiotensin II -induced cardiac hypertrophy. Trends Pharmacol Sci 24:239-244.
26. Shenouda A, Douglas SA, Ohlstein EH, Giaid A. 2002. Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J Histochem Cytochem 50:885-889.
27. Song W, Abdel-Razik AE, Lu W, Ao Z, Johns DG, Douglas SA, Balment RJ, Ashton N. 2006. Urotensin II and renal function in the rat. Kidney Int 69:1360-1368.
28. Tibbles LA, Woodgett JR. 1999. The stress-activated protein kinase pathways. Cell Mol Life Sci 55:1230-1254.
29. Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, Kimura Y, Sasano H, Murakami O. 2001. Role of urotensin II in patients on dialysis. Lancet 358:810-811.
30. Totsune K, Takahashi K, Arihara Z, Sone M, Murakami O, Ito S, Kikuya M, Ohkubo T, Hashimoto J, Imai Y. 2004. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with type 2 diabetes mellitus: Association with progress of diabetic nephropathy. Peptides 25:1809-1814.
31. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE, Krum H. 2003. Direct actions of urotensin II on the heart: Implications for cardiac fibrosis and hypertrophy. Circ Res 93:246-253.